These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 25911079)

  • 1. Gender-related lipid and/or lipoprotein responses to statins in subjects in primary and secondary prevention.
    Mombelli G; Bosisio R; Calabresi L; Magni P; Pavanello C; Pazzucconi F; Sirtori CR
    J Clin Lipidol; 2015; 9(2):226-33. PubMed ID: 25911079
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effectiveness of the addition of ezetimibe to ongoing statin therapy in modifying lipid profiles and attaining low-density lipoprotein cholesterol goals in older and elderly patients: subanalyses of data from a randomized, double-blind, placebo-controlled trial.
    Pearson T; Denke M; McBride P; Battisti WP; Brady WE; Palmisano J
    Am J Geriatr Pharmacother; 2005 Dec; 3(4):218-28. PubMed ID: 16503317
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evidence supporting primary prevention of cardiovascular diseases with statins: Gaps between updated clinical results and actual practice.
    Bruckert E; Ferrières J
    Arch Cardiovasc Dis; 2014 Mar; 107(3):188-200. PubMed ID: 24613429
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.
    Cziraky MJ; Watson KE; Talbert RL
    J Manag Care Pharm; 2008 Oct; 14(8 Suppl):S3-28; quiz S30-1. PubMed ID: 19891279
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Consistency in efficacy and safety of ezetimibe coadministered with statins for treatment of hypercholesterolemia in women and men.
    Bennett S; Sager P; Lipka L; Melani L; Suresh R; Veltri E;
    J Womens Health (Larchmt); 2004 Dec; 13(10):1101-7. PubMed ID: 15650343
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Women Versus Men: Is There Equal Benefit and Safety from Statins?
    Plakogiannis R; Arif SA
    Curr Atheroscler Rep; 2016 Feb; 18(2):6. PubMed ID: 26782824
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Number needed to treat with rosuvastatin to prevent first cardiovascular events and death among men and women with low low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin (JUPITER).
    Ridker PM; MacFadyen JG; Fonseca FA; Genest J; Gotto AM; Kastelein JJ; Koenig W; Libby P; Lorenzatti AJ; Nordestgaard BG; Shepherd J; Willerson JT; Glynn RJ;
    Circ Cardiovasc Qual Outcomes; 2009 Nov; 2(6):616-23. PubMed ID: 20031900
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association between persistence with statin therapy and reduction in low-density lipoprotein cholesterol level: analysis of real-life data from community settings.
    Shalev V; Goldshtein I; Halpern Y; Chodick G
    Pharmacotherapy; 2014 Jan; 34(1):1-8. PubMed ID: 23836549
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Persistent lipid abnormalities in statin-treated patients and predictors of LDL-cholesterol goal achievement in clinical practice in Europe and Canada.
    Gitt AK; Drexel H; Feely J; Ferrières J; Gonzalez-Juanatey JR; Thomsen KK; Leiter LA; Lundman P; da Silva PM; Pedersen T; Wood D; Jünger C; Dellea PS; Sazonov V; Chazelle F; Kastelein JJ;
    Eur J Prev Cardiol; 2012 Apr; 19(2):221-30. PubMed ID: 21450578
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Meta-analysis of comparative efficacy of increasing dose of Atorvastatin versus Rosuvastatin versus Simvastatin on lowering levels of atherogenic lipids (from VOYAGER).
    Nicholls SJ; Brandrup-Wognsen G; Palmer M; Barter PJ
    Am J Cardiol; 2010 Jan; 105(1):69-76. PubMed ID: 20102893
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gender disparities in evidence-based statin therapy in patients with cardiovascular disease.
    Virani SS; Woodard LD; Ramsey DJ; Urech TH; Akeroyd JM; Shah T; Deswal A; Bozkurt B; Ballantyne CM; Petersen LA
    Am J Cardiol; 2015 Jan; 115(1):21-6. PubMed ID: 25456865
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic practice patterns related to statin potency and ezetimibe/simvastatin combination therapies in lowering LDL-C in patients with high-risk cardiovascular disease.
    Toth PP; Foody JM; Tomassini JE; Sajjan SG; Ramey DR; Neff DR; Tershakovec AM; Hu XH; Tunceli K
    J Clin Lipidol; 2014; 8(1):107-16. PubMed ID: 24528691
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Justification for the Use of Statins in Primary Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER)--can C-reactive protein be used to target statin therapy in primary prevention?
    Mora S; Ridker PM
    Am J Cardiol; 2006 Jan; 97(2A):33A-41A. PubMed ID: 16442935
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacogenomics of lipid-lowering therapies.
    Hu M; Tomlinson B
    Pharmacogenomics; 2013 Jun; 14(8):981-95. PubMed ID: 23746191
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Low high-density lipoprotein cholesterol is not a risk factor for recurrent vascular events in patients with vascular disease on intensive lipid-lowering medication.
    van de Woestijne AP; van der Graaf Y; Liem AH; Cramer MJ; Westerink J; Visseren FL;
    J Am Coll Cardiol; 2013 Nov; 62(20):1834-41. PubMed ID: 23948286
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Primary prevention with statins and incident diabetes in hypertensive patients at high cardiovascular risk.
    Izzo R; de Simone G; Trimarco V; Giudice R; De Marco M; Di Renzo G; De Luca N; Trimarco B
    Nutr Metab Cardiovasc Dis; 2013 Nov; 23(11):1101-6. PubMed ID: 23419735
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cardiovascular risk reduction: what do recent trials with rosuvastatin tell us?
    Fabbri G; Maggioni AP
    Adv Ther; 2009 May; 26(5):469-87. PubMed ID: 19444394
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gender differences in achieving optimal lipid goals in patients with coronary artery disease.
    Victor BM; Teal V; Ahedor L; Karalis DG
    Am J Cardiol; 2014 May; 113(10):1611-5. PubMed ID: 24698458
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lipid-lowering therapy with statins for the primary and secondary prevention of cardiovascular disease.
    Lardizabal JA; Deedwania P
    Cardiol Clin; 2011 Feb; 29(1):87-103. PubMed ID: 21257102
    [TBL] [Abstract][Full Text] [Related]  

  • 20. What do the statins tell us?
    LaRosa JC
    Am Heart J; 2002 Dec; 144(6 Suppl):S21-6. PubMed ID: 12486412
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.